These efficacy variables appeared greater at higher doses , although there are no significant differences between 10 and 20 mg dose .
Specific adverse events with vardenafil  included flushing , dyspepsia , headache , and rhinitis .
Vardenafil was not significantly associated with serious cardiovascular events or death .
Vardenafil , in all treatment regimens , shows to possess superior efficacy to placebo in the treatment of patients with erectile dysfunction .
Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction.
OBJECTIVE To assess the efficacy of oral sildenafil in diabetic men with severe erectile dysfunction ( ED ) , who are successfully treated with intracavernous injections of  vasoactive drugs . METHODS 81 impotent diabetic men ( 29 with type 1 and 52 with type 2 ) were treated for 1 - 7 years with  self-injections . 13 men were treated with 10 microg and 15 with 20 microg of prostagl and in E1 ( PGE1 ) , and 53 with a mixture of PGE1 20 microg and papaverine 7.5 - 40 mg ( MIX ) . After a 1-week washout period , they changed to oral sildenafil in titrating doses up to 100 mg . The change was successful if the man achieved an erection and penetration even once . RESULTS Sildenafil was discontinued in 23 men because of insufficiency . Eleven men ( 13.6 % ) , all with type 2 diabetes , responded to sildenafil ( 10 previously treated with 10 microg and 1 with 20 microg of PGE1 , none treated with MIX ) . Thus , 39.2 % of the treated with PGE1 responded to oral sildenafil . The response was influenced by the age , the type of diabetes ( type 2 ) and the kind of the previously injected drug ( PGE1 10 microg ) ; it was not influenced by the duration of diabetes , ED and treatment with self-injections . CONCLUSIONS Despite the well documented efficacy of sildenafil , self-injections continue to be the solely effective therapeutic modality in many diabetic men afflicted by severe ED . Only the younger men with non-insulin-dependent diabetes , treated with low doses of PGE1 are more likely to respond to oral sildenafil and change treatment . Men with insulin-dependent diabetes or treated with mixtures of vasoactive drugs are not likely to respond to oral sildenafil
These efficacy variables appeared greater at higher doses , although there are no significant differences between 10 and 20 mg dose .
Specific adverse events with vardenafil  included flushing , dyspepsia , headache , and rhinitis .
Vardenafil was not significantly associated with serious cardiovascular events or death .
Vardenafil , in all treatment regimens , shows to possess superior efficacy to placebo in the treatment of patients with erectile dysfunction .